The Role of PK Data in Early Clinical Development
Pharmacokinetic data is the foundation on which dose selection decisions are built in early clinical development. Before the first human dose is administered, the preclinical PK profile provides predictions of human exposure based on allometric scaling or physiologically based pharmacokinetic (PBPK) modelling. After the first dose in humans, that prediction is tested against reality, and the clinical PK data that emerges drives every subsequent dosing decision.
For a single ascending dose (SAD) study, PK data from each cohort determines whether escalation to the next dose level is appropriate. For a multiple ascending dose (MAD) study, trough concentrations at steady state confirm whether the dosing interval produces adequate drug exposure between doses. For a food effect study, the comparison of AUC and Cmax in fed and fasted states informs whether the drug needs to be taken with or without food. In each case, the quality of the bioanalytical data directly limits the quality of the clinical decision.
Building the Analytical Method for a New Molecule
Selectivity and Matrix Selection
The first task in developing a bioanalytical method for a new small molecule is establishing selectivity: can the method measure the drug accurately in the presence of the endogenous components of the biological matrix? For most plasma or serum methods, selectivity is demonstrated by showing that the analyte signal in drug-free matrix samples from at least six individual donors is within 20% of the lower limit of quantification (LLOQ), confirming that matrix components do not produce a false signal at the analyte’s retention time and mass transition.
Sensitivity and LLOQ
The LLOQ defines the lowest concentration that can be measured with acceptable precision and accuracy, typically defined as a coefficient of variation below 20% and a bias within plus or minus 20% of the nominal value. Setting the LLOQ appropriately requires an estimate of the lowest plasma concentration expected in the clinical study, which for a SAD study is typically the Cmax at the lowest dose level adjusted for the expected elimination over the last sampling timepoint. For molecules with very long half-lives or very wide dose ranges, the LLOQ requirement may span several orders of magnitude.
Metabolite Coverage
For many small molecules, metabolites are present in plasma at concentrations that can be clinically significant, either because the metabolite is pharmacologically active or because it is associated with toxicity. Regulatory guidance, including the FDA’s 2020 guidance on safety testing of drug metabolites, requires that metabolites present at greater than 10% of parent drug exposure are characterised and assessed for safety. The bioanalytical method must be capable of measuring the relevant metabolites in addition to the parent compound if their concentrations are expected to be clinically relevant.
LC-MS/MS: The Gold Standard for Small Molecule PK
Liquid chromatography tandem mass spectrometry (LC-MS/MS) is the primary analytical platform for quantitative small molecule bioanalysis in regulatory studies. The combination of chromatographic separation with mass selective detection provides the specificity needed to measure a drug and its metabolites at nanomolar or sub-nanomolar concentrations in complex biological matrices, with precision and accuracy that consistently meets ICH M10 acceptance criteria across a wide range of analytes.
Key method development parameters for an LC-MS/MS assay include the choice of ionisation mode (positive or negative electrospray ionisation based on the molecule’s ionisable groups), the chromatographic conditions (stationary phase, mobile phase composition, gradient profile), the mass transitions monitored (typically the precursor ion to at least two fragment ions for confirmation of identity), and the sample preparation approach (protein precipitation, liquid-liquid extraction, or solid-phase extraction based on the required sensitivity and selectivity).
From Single Dose to Steady State: What the PK Data Tells You
| PK Study Phase | Key Measurements | Clinical Decision Supported |
| Single ascending dose (SAD) | Cmax, AUC0-t, AUC0-inf, t1/2, Tmax at each dose level | Dose proportionality; human half-life; dose selection for MAD study |
| Multiple ascending dose (MAD) | Cmin (trough) at steady state; AUCss; accumulation ratio | Dosing interval confirmation; time to steady state; accumulation characterisation |
| Food effect study | AUC and Cmax in fed vs fasted state; 90% CI for the ratio | Fasting or fed administration instruction; effect of food on variability |
| Special population PK | Clearance and exposure in renally or hepatically impaired subjects | Dose adjustment recommendations for labelling |
| Drug-drug interaction studies | PK of victim drug with and without perpetrator | Labelling of clinically relevant DDIs; dose adjustment requirements |
Sample Management and Chain of Custody
The quality of bioanalytical data depends not only on the analytical method but on the handling of the samples from the moment of collection to the moment of analysis. Blood must be collected into the correct anticoagulant tube, processed to plasma or serum within the validated time window, aliquoted correctly, and stored at the validated temperature. Deviations from the validated sample handling procedure can result in analyte degradation that produces systematically low concentrations, invalidating the data.
Ardena’s clinical team at Assen provides sample management services that coordinate sample receipt from clinical sites, log chain of custody, and confirm that sample handling conditions were within validated parameters before analysis proceeds. Samples that have experienced documented excursions are flagged for scientific review before inclusion in the dataset.
Ardena’s Small Molecule PK Bioanalysis at Assen
Ardena’s bioanalytical laboratory in Assen provides fully validated LC-MS/MS methods for small molecule PK studies from early non-clinical through to Phase III. The laboratory operates under GLP and GCP conditions for regulated studies, with ICH M10 compliant validation packages and ISR programmes as standard. The team has experience with plasma, serum, urine, cerebrospinal fluid, and tissue matrices across a wide range of therapeutic areas.
